BioArctic AB’s partner Eisai announced that that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for less frequent monthly lecanemab-irmb intravenous maintenance dosing.
BioArctic AB’s partner Eisai announced that that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for less frequent monthly lecanemab-irmb intravenous maintenance dosing.